A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer
ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy for solid tumors is limited by antigen heterogeneity and T cell exhaustion. To address these limitations, we develop a novel multi‐targeting “Bicephali” CAR‐T platform featuring a dual‐transmembrane protein with two distinct extracellular antigen‐binding domains a...